SAGE News and Press, Sage Therapeutics Inc. From 11/02/21

FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And in the bigger scenario of a massive $11-trillion-plus global...

Sage Therapeutics (NASDAQ:SAGE) posted third-quarter revenue and profit that missed Wall Street estimates and provided an update on its drug development pipeline. Quarterly revenue fell over 12% to $1.44M, missing analysts' average estimate by $0.53M. Research and development expenses were $8...

Sage Therapeutics (NASDAQ:SAGE): Q3 GAAP EPS of -$2.21 misses by $0.36. Revenue of $1.44M (-12.2% Y/Y) misses by $0.53M. Press Release Continued pipeline progress demonstrated across brain health franchises, with plans to initiate three Phase 2 studies across SAGE-324 and SAGE-718 programs. ...

NDA submission for zuranolone for the treatment of MDD expected to be filed in the second half of 2022, with rolling submission planned to begin in early 2022 CORAL Study primary endpoint updated, in line with goal of study to demonstrate rapid reduction in depressive symptoms...

Sage Therapeutics (NASDAQ:SAGE) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, before market open. The consensus EPS Estimate is -$1.86 and the consensus Revenue Estimate is $1.97M (+20.1% Y/Y). Sage shares rose more than 8% in reaction to posting a narr...

Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been legal for quite some time. Ketamine was originally popul...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Tuesday, November 2, 2021 at 8:00 a.m....

Following the pre-NDA meeting, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD The planned initial submission package will be for the treatment of MDD with an anticipated PPD filin...

FN Media Group Presents Oilprice.com Market Commentary London – October 18, 2021 – A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the same way that Amazon disrupted the ret...

With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a decline in their stock prices. Regeneron Pharmaceuticals Regeneron Pharmaceut...